Immunoglobulin A

Athens Research

Immunoglobulin A

9

Antisera Production, In Vitro Diagnostic, Glycoproteomics, ELISA, Cancer, Chromatography Binding, Anaphalaxis, Infection, Autoimmune Diseases, Kidney Injury, Rheumatoid Arthritis

Research Use Only

≥98% by SDS-PAGE

Serum immunoglobulin A (IgA) constitutes the second most abundant antibody class in human plasma (0.4–2.2 mg/mL), existing predominantly as monomeric IgA1 (80%) with lesser IgA2 contributions. Unlike secretory IgA-a dimeric mucosal protector featuring J-chains and a secretory component-serum IgA engages FcalfaRI (CD89) on myeloid cells to orchestrate systemic immunity. Monomeric serum IgA suppresses inflammation via inhibitory ITAMi signaling, while immune complexes activate phagocytosis, cytokine release, and antibody-dependent cellular cytotoxicity, balancing pathogen clearance and tissue homeostasis. Dysregulation of serum IgA underpins multiple pathologies. Selective IgA deficiency (sIgAD), the most common primary immunodeficiency, elevates risks for recurrent infections and autoimmune disorders like systemic lupus erythematosus (SLE) and celiac disease. Conversely, elevated serum IgA associates with IgA nephropathy, where galactose-deficient IgA1 deposits in renal glomeruli trigger complement-mediated inflammation and progressive kidney failure. Hyper-IgA levels may also signal immunodeficiency syndromes or multiple myeloma, particularly when beta-migrating monoclonal proteins complicate electrophoresis interpretation. The IgA2 subclass, distinguished by reduced sialylation, exhibits heightened pro-inflammatory activity linked to rheumatoid arthritis severity. Clinically, serum IgA quantification aids immunodeficiency diagnosis and myeloma monitoring, where nephelometric assays outperform traditional electrophoresis. Therapeutic strategies targeting FcalfaRI or aberrant IgA production, such as monoclonal antibodies against B-cell activating factor (BAFF), show promise in autoimmune and renal diseases. Additionally, engineered IgA antibodies are being explored for enhanced neutrophil-mediated tumor cytotoxicity, highlighting its expanding translational potential.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

≤ -80° C

41116100